Vanadyl Sulfate
1. Identity: Chemical Name, Composition, and Natural Sources
Vanadyl sulfate (also written vanadyl sulphate) is the most widely recognized supplemental form of the trace element vanadium. Vanadyl(IV) sulfate describes a collection of inorganic compounds of vanadium with the formula VOSO₄(H₂O)ₓ, where 0 ≤ x ≤ 6. This hygroscopic blue salt is one of the most common sources of vanadium in the laboratory, reflecting its high stability, and features the vanadyl ion, VO²⁺, which has been called the "most stable diatomic ion."
The compound has the CAS registry number 27774-13-6 and the molecular formula VOSO₄. The anhydrous form occurs as the mineral pauflerite, of fumarolic origin, while hydrated forms include a hexahydrate (stanleyite), pentahydrates (minasragrite, orthominasragrite, and anorthominasragrite), and a trihydrate (bobjonesite). The pentahydrate is the most common hydrated form.
Vanadium itself is a transition metal with the chemical symbol V and atomic number 23. The element usually combines with other elements such as oxygen, sodium, sulfur, or chloride, and occurs naturally in about 65 different minerals and in fossil fuel deposits. Vanadium is the 22nd most abundant element in the Earth's crust. Vanadium is found in about 65 different minerals; carnotite, roscoelite, vanadinite, and patronite are important sources of this metal, along with bravoite and davidite.
Vanadium is a naturally occurring element that is widely distributed in the environment; it is present in air, soil, food, and water, either from natural sources or from industrial ones, and is widely used in steel-making and oil combustion. Vanadium is found in very small amounts in a wide variety of foods, including seafood, cereals, mushrooms, parsley, corn, soy, and gelatin. The best food sources of vanadium are mushrooms, shellfish, black pepper, parsley, dill weed, beer, wine, grain and grain products, and artificially sweetened drinks.
Vanadyl sulfate is an intermediate in the extraction of vanadium from petroleum residues and is also a component of some food supplements and drugs. It is most commonly obtained by reduction of vanadium pentoxide with sulfur dioxide. Regarding dietary intake, an average diet may provide 6–20 micrograms of vanadium daily. Other estimates place this slightly higher: an average diet provides 15–30 mcg per day.
Common Forms and Preparations
Vanadium exists as both vanadyl sulfate, the form most commonly used in supplements, and vanadate. Vanadyl sulfate is most commonly found in nutritional supplements. It is sold as stand-alone oral capsules and tablets, and also incorporated into multi-ingredient formulations marketed to athletes and persons with metabolic concerns. Up to 60 mg/day of vanadyl sulfate, equivalent to 18.6 mg elemental vanadium per day, has been reported to be used by weight-training athletes.
2. Traditional and Historical Use
The medicinal use of vanadium compounds predates the discovery of insulin by more than two decades. The first report of vanadium salts being used as a metallotherapeutic appeared in 1899. Consistent with medical trials of that era, Lyonnet and his colleagues first tried the proposed drug on themselves, then on 60 of their patients (three of whom were diabetic) over a period of some months. They described what might be considered today a "Phase 0" clinical trial: 4–5 mg sodium metavanadate (before meals) every 24 hours, three times per week, with two out of the three diabetic patients said to have obtained a slight, transient lowering of sugar levels. No ill effects were noted in any of their patients.
The discovery of insulin in 1922 and its almost immediate adoption as the treatment of choice in diabetes mellitus led to a long hiatus for the medicinal use of vanadium compounds. Early interest in vanadium as a metallotherapeutic waned, even as exploration of vanadium's biological effects in plants and animals continued.
At the end of the 1970s, the insulin-like effect of vanadium compounds in several experimental models was consolidated, among them the stimulation of glucose transport, glycolysis, and glycosynthesis, among other carbohydrate metabolism events. This revival of scientific interest eventually led to the testing of vanadyl sulfate specifically as a dietary supplement and experimental antidiabetic agent in the 1980s and 1990s. Vanadium has also been used as a dietary supplement for treating low blood sugar, high cholesterol, heart disease, tuberculosis, syphilis, anemia, and edema, and for preventing cancer, though many of these historical applications lack rigorous clinical evidence.
The awareness of vanadium's physiological effects dates to the 1960s, and although the specific mechanisms mediating its physiological functions remain unknown, researchers have explored its potential application as a source for antitumor, anti-HIV, antituberculosis, and particularly antidiabetic therapeutics.
3. Key Constituents, Active Compound, and Mechanisms of Action
Vanadyl sulfate delivers vanadium in the +4 oxidation state as the vanadyl cation (VO²⁺). Upon ingestion, it undergoes speciation and interacts with multiple biochemical pathways. The primary mechanisms proposed by the scientific literature are described below.
Protein Tyrosine Phosphatase (PTP) Inhibition
Vanadium salts such as vanadyl sulfate (VS), as potent inhibitors of protein tyrosine phosphatases, have been shown to mimic, augment, and prolong insulin's action. A number of vanadium compounds, including vanadate, vanadyl sulfate, and metavanadate, have insulin-mimicking actions both in vitro and in vivo. They have multiple biological effects in cultured cells and interact directly with various enzymes. The inhibitory action on phosphoprotein tyrosine phosphatases (PTPs) and enhancement of cellular tyrosine phosphorylation appear to be the most relevant to explain the ability to mimic insulin.
More specifically, the enzyme PTP1B plays a crucial role in the signaling of the insulin receptor, because it is a negative regulator of the pathway. The antidiabetic activity of vanadium compounds is linked to the formation of a transition-state stable analogue which binds strongly to the active site of PTP1B, leading to its inhibition. Unlike the phosphoester, vanadate esters bound to the active site of the enzyme are not easily released, causing inhibition of PTP activity.
Insulin Receptor Kinase and Downstream Signaling
In rat adipocytes, both acute insulin effects — including stimulation of IGF-II and transferrin binding — and a chronic effect, insulin receptor downregulation, were stimulated by vanadate. Vanadate also enhanced insulin binding, particularly at very low insulin concentrations, associated with increased receptor affinity. This resulted in increased adipocyte insulin sensitivity. Finally, vanadate augmented the extent of activation of the insulin receptor kinase by submaximal insulin concentrations. In conclusion, vanadate promotes insulin action in rat adipocytes by three mechanisms: a direct insulin-mimetic action, an enhancement of insulin sensitivity, and a prolongation of the insulin biological response.
PI3-Kinase and PKB/Akt Pathway
Another mechanism of reduction of blood glucose levels by vanadium compounds is the activation of PKB/Akt kinase, leading to the increase of glucose uptake by the GLUT4 transporter. Treatment of insulin receptor-overexpressing cells with insulin or vanadyl sulfate resulted in a time-dependent transient increase in phosphorylation and activation of extracellular signal-regulated kinases 1 and 2 (ERK 1/2) that peaked at about 5 minutes, then declined rapidly. However, when cells were treated with vanadyl sulfate before stimulation with insulin, sustained ERK 1/2 phosphorylation and activation were observed well beyond 60 minutes.
Inhibition of cAMP-Dependent Protein Kinase (PKA)
The hypothesis that vanadium compounds act by inhibiting protein tyrosine phosphatases has attracted most support. However, studies have further evaluated the possibility that vanadyl sulfate trihydrate can also inhibit 3',5'-cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA). Using conventional assay conditions, vanadyl sulfate inhibited PKA only at high concentrations (IC₅₀ > 400 μM); however, PKA inhibition was seen at dramatically lower concentrations (IC₅₀ < 10 μM) when sequestration of vanadyl ions was minimized. Vanadyl appears to be the effective PKA inhibitor, because sodium orthovanadate did not inhibit PKA.
Glucose Transport and Metabolism
The improved insulin sensitivity induced by vanadyl sulfate is in line with numerous studies indicating that vanadium can be considered as a potent insulin mimetic or insulin trophic in various tissues. Vanadium compounds are characterized by multiple ways of action resulting in blood sugar decrease. In vivo and in vitro studies have reported that vanadyl sulfate increased glucose transport and metabolism in skeletal muscles, liver, and adipose tissues.
Bioavailability Limitations
The absorption of ingested vanadium is less than 5 percent, and therefore most ingested vanadium is found in the feces. Absorbed vanadate is converted to the vanadyl cation, which can complex with ferritin and transferrin in plasma and body fluids. Highest concentrations of vanadium are found in the liver, kidney, and bone. However, very little of the absorbed vanadium is retained in the body. Because vanadyl sulfate is not well absorbed, a number of organic vanadium compounds have been synthesized and tested. One of these, bismaltolato-oxovanadium(IV) (BMOV), has shown promise as a therapeutic agent and is 2–3 times more potent than vanadyl sulfate with less toxicity.
4. Scientific Evidence by Area of Use
4.1 Glycemic Control and Type 2 Diabetes
This is the area with the most scientific investigation. Evidence spans animal models, in vitro studies, and a small number of human clinical trials.
Human Clinical Evidence: Vanadyl sulfate (VOSO₄) is an oxidative form of vanadium that in vitro and in animal models of diabetes has been shown to reduce hyperglycemia and insulin resistance. Small clinical studies of 2- to 4-week duration in type 2 diabetes had led to inconsistent results. To define its efficacy and mechanism of action, 11 type 2 diabetic patients were treated with VOSO₄ at a higher dose (150 mg/day) and for a longer period of time (6 weeks) than in previous studies. Treatment significantly improved glycemic control: fasting plasma glucose decreased from 194 ± 16 to 155 ± 15 mg/dL, hemoglobin A1c decreased from 8.1 ± 0.4 to 7.6 ± 0.4%, and fructosamine decreased from 348 ± 26 to 293 ± 12 μmol/L (all P < 0.01) without any change in body weight. Vanadyl sulfate reduced endogenous glucose production (EGP) by about 20% (P < 0.01), and also caused a modest increase in insulin-mediated glucose disposal (from 4.3 ± 0.4 to 5.1 ± 0.6 mg/kg lean body mass·min; P < 0.03).
A separate dose-ranging study examined three doses in a larger cohort: to investigate the efficacy and mechanism of action of vanadium salts as oral hypoglycemic agents, 16 type 2 diabetic patients were studied before and after 6 weeks of vanadyl sulfate treatment at three doses. Glucose metabolism during a euglycemic insulin clamp did not increase at 75 mg/day, but improved in 3 of 5 subjects receiving 150 mg VOSO₄ and 4 of 8 subjects receiving 300 mg VOSO₄. Basal hepatic glucose production and suppression of hepatic glucose production by insulin were unchanged at all doses. Fasting glucose and hemoglobin A1c decreased significantly in the 150- and 300-mg VOSO₄ groups. At the highest dose, total cholesterol decreased, associated with a decrease in high-density lipoprotein (HDL).
Systematic Review: A 2008 systematic review (Smith, Pickering, and Lewith; published in QJM) applied stringent inclusion criteria to assess the evidence base. Selection criteria included controlled human trials of vanadium versus placebo in adults with type 2 diabetes of minimum 2 months' duration, with a minimum of 10 subjects per arm. Data extraction and assessment of study quality were undertaken by two independent reviewers. Results showed that 151 studies were found but none met the inclusion criteria. Applying revised, less restrictive criteria for clinical trials of 30–150 mg daily oral vanadium supplementation in diabetic humans, only five studies were identified. This systematic review suggests that most vanadium supplementation studies have been unable to show sufficient evidence to support its use for glycemic control in type 2 diabetes. Vanadium may have potential in improving glucose tolerance, but its role in diabetes has been explored in very small-scale studies. More rigorous evidence showing the use of oral vanadium supplementation to improve glycemic control in type 2 diabetes is required. Definitive randomized controlled trials would be needed to establish the efficacy of the antidiabetic potential of vanadium compounds.
Evidence strength: The available clinical evidence is preliminary and based on small, mostly uncontrolled or inadequately powered studies. The results are directionally positive for glycemic markers (fasting glucose, HbA1c) in type 2 diabetes at doses of 150 mg/day and above, but no large-scale, placebo-controlled randomized trial meeting modern standards has been completed. The evidence does not currently support clinical recommendation.
4.2 Insulin Resistance and Insulin Sensitivity
The pathophysiologic importance of insulin resistance in diseases such as obesity and diabetes mellitus has led to great interest in defining the mechanism of insulin action as well as the means to overcome the biochemical defects responsible for the resistance. Vanadium compounds have been discovered to mimic many of the metabolic actions of insulin both in vitro and in vivo and improve glycemic control in human subjects with diabetes mellitus. Apart from its direct insulinmimetic actions, vanadate modulates insulin metabolic effects by enhancing insulin sensitivity and prolonging insulin action, and all of these actions appear to be related to protein tyrosine phosphatase (PTP) inhibition.
The study by Cusi et al. (2001) treated 11 type 2 diabetic patients with 150 mg/day of vanadyl sulfate for a period of 6 weeks. Vanadyl sulfate administration improved glycemic control, and the treatment was well tolerated with rather uncommon side effects, which were mainly related to the gastrointestinal tract. According to PubMed and Scopus, this was the last study in humans until 2008.
Evidence strength: Mechanistic evidence from cell culture and animal models is robust. Human evidence for insulin sensitivity improvement (measured by euglycemic clamp) is limited by small sample sizes and short durations.
4.3 Lipid Profile
Effects on lipid parameters have been observed in both animal studies and, to a limited extent, in humans. In streptozotocin-diabetic rats, after 60 days of treatment, vanadyl sulfate reversed diabetic elevations in serum cholesterol, LDL-cholesterol, triglycerides, phospholipids, VLDL-cholesterol, and lipid peroxidation, and reversed the reduction in serum HDL-cholesterol. In the Cusi et al. (2001) human trial, vanadyl sulfate treatment lowered plasma total cholesterol. However, in the dose-ranging human study, at the highest dose (300 mg/day), total cholesterol decreased but this was associated with a decrease in high-density lipoprotein (HDL).
Evidence strength: Animal data are consistent; the human lipid data are mixed and limited. The decrease in HDL observed at the highest dose is a potential concern that has not been adequately characterized.
4.4 Athletic Performance and Body Composition
Vanadyl sulfate attracted attention in the sports nutrition market during the 1990s on the hypothesis that its insulin-mimetic properties would promote glucose and amino acid uptake into muscle. However, the sole controlled human trial directly addressing this question did not confirm the hypothesis.
The effects of oral vanadyl sulfate (VOSO₄) at 0.5 mg/kg/day on anthropometry, body composition, and performance were investigated in a 12-week, double-blind, placebo-controlled trial involving weight-training volunteers. Performance was assessed using 1- and 10-repetition maximum (RM) for the bench press and leg extension. Thirty-one subjects completed the trial, with 2 vanadyl sulfate subjects withdrawing because of apparent side effects. There were no significant treatment effects for anthropometric parameters and body composition during the trial. Both groups had significant improvements in performance, but the only significant effect of treatment was a Treatment × Time interaction in the 1 RM leg extension (P = 0.002), which could have arisen because the vanadyl sulfate group had a lower performance at baseline in this test. In this same trial, no vanadyl-related effects were found on body weight, blood pressure, hematological indices, blood viscosity, or on biochemical parameters relating to liver and kidney function or lipid metabolism.
Most studies indicate that chromium, vanadyl sulfate, and boron supplementation do not affect muscle growth. Vanadium is sometimes advertised as a sports supplement, but there is no evidence that it boosts performance. In fact, one clinical trial examining vanadium use in athletes found no benefit at all.
Evidence strength: The controlled human trial does not support performance or body composition benefits in healthy weight-training athletes. Evidence is weak and does not support use for athletic enhancement.
4.5 Bone Metabolism
Research into vanadyl sulfate and bone health is primarily preclinical. Mammalian and avian in vitro bone-derived cell systems have been used to identify cellular mechanisms and signaling pathways involved in the bone-related effects of vanadium compounds. It was shown that vanadate, vanadyl (+4), and various vanadium complexes regulate osteoblast-like cell proliferation and differentiation. In general, low concentrations have a stimulatory effect, while higher amounts inhibit cell proliferation and alkaline phosphatase (ALP) activity. Vanadate was also shown to stimulate the synthesis of collagen, the main component of osteoblast extracellular matrix.
Evidence strength: Exclusively preclinical (animal and cell culture). No controlled human trials on vanadyl sulfate and bone outcomes have been identified in the literature.
4.6 Beta-Cell Regeneration (Preclinical)
The improved insulin sensitivity induced by vanadyl sulfate is in line with numerous studies indicating that vanadium can be considered a potent insulin mimetic or insulin trophic in various tissues. Vanadium compounds are characterized by multiple ways of action resulting in blood sugar decrease. Animal model research has also examined the possibility that vanadyl sulfate promotes beta-cell proliferation and regeneration in pancreatic islets, though this evidence is limited to preclinical models.
Evidence strength: Preclinical only. No human data.
5. Body Systems and Health Areas Associated with Vanadyl Sulfate
- Endocrine / Metabolic system: Insulin sensitivity, glucose homeostasis, glycemic control; insulin receptor signaling pathways.
- Pancreas: Beta-cell function and potential trophic effects (preclinical).
- Cardiovascular system: Lipid modulation (mixed human evidence); blood pressure effects in animal hypertension models.
- Musculoskeletal system: Bone metabolism (preclinical); skeletal muscle glucose uptake (in vitro and animal).
- Hepatic system: Liver glucose production suppression (human evidence at 150 mg/day); potential hepatotoxicity at high doses.
- Renal system: Primary site of vanadium accumulation; subject to potential nephrotoxicity at higher doses.
6. Dosage Forms and Dosages Reported in Studies
Vanadyl sulfate is administered orally in capsule or tablet form. The following dosages have been reported in the scientific literature:
- In a human study of 16 type 2 diabetic patients, three doses were evaluated over 6 weeks: 75 mg/day, 150 mg/day, and 300 mg/day. Glucose metabolism improved in 3 of 5 subjects at 150 mg/day and 4 of 8 subjects at 300 mg/day; the 75 mg/day dose showed no significant improvement.
- Cusi et al. (2001) treated 11 type 2 diabetic patients with 150 mg/day for 6 weeks, which was at a higher dose and for a longer period than in previous studies.
- The 12-week athletic performance trial used 0.5 mg/kg/day in weight-training volunteers.
- There is some evidence that high doses of vanadyl sulfate (100 mg daily, providing 31 mg elemental vanadium) might improve the way people with type 2 diabetes use insulin.
- Vanadium was historically promoted at doses ranging from 15 to 100 mg of vanadyl sulfate daily.
- The Institute of Medicine set the Tolerable Upper Intake Level (UL) for vanadium in adults at 1.8 mg/day, based on animal data. Doses used in diabetes clinical trials (e.g., 150–300 mg of vanadyl sulfate per day) far exceed this UL, underscoring the experimental nature of such regimens.
It should be noted that although insulin requirements were decreased in patients with type 1 diabetes in some supplementation studies, the doses of vanadium used were about 100 times the usual intakes, and they greatly exceed the Tolerable Upper Intake Level for vanadium.
7. Safety Considerations and Interactions
7.1 Essential Status and Dietary Reference Intakes
The essentiality of vanadium in human physiology has been a subject of great debate but remains largely unproven. In humans, vanadium deficiency has been reported, while its acute and chronic toxicity has been also extensively documented. Neither Adequate Intakes nor Recommended Dietary Allowances were proposed for vanadium by the Institute of Medicine. Deficiencies of vanadium have not been reported in humans, and it is not known whether this mineral is essential for humans.
7.2 Tolerable Upper Intake Level
Estimates of Tolerable Upper Intake Levels were set for boron, nickel, and vanadium. The UL for vanadium is based on animal data and has been set for adults at 1.8 mg/day. This figure is markedly lower than the doses used in clinical diabetes trials (typically 75–300 mg of vanadyl sulfate per day).
7.3 Gastrointestinal Adverse Effects
In human studies, vanadyl sulfate administration was well tolerated with rather uncommon side effects, which were mainly related to the gastrointestinal tract. Exposure to high doses of vanadium compounds may cause gastrointestinal symptoms, including diarrhea and vomiting, leading to decreased fluid and food intake, dehydration, and weight reduction.
7.4 Renal and Hepatic Toxicity
Gastrointestinal disturbance, such as diarrhea, and liver and kidney toxicity are severe adverse effects noted following vanadium treatment of diabetic animals, possibly due to generation of reactive oxygen species. Dietary vanadium intake has been reported to induce renal and hepatic toxicity through oxidative damage and vanadium accumulation. Oral exposure for an intermediate duration produced the highest accumulation of vanadium in the kidney. Adult rats exposed to 5 or 50 ppm vanadium in the drinking water for 3 months had the highest vanadium levels in the kidney, followed by bone, liver, and muscle.
There is developing evidence that vanadium might harm the kidneys. Vanadium is considered unsafe when used in large amounts and for a long time, as this increases the risk of serious side effects including kidney damage.
Importantly, the discontinuation of the pharmaceutical development of BEOV (a second-generation vanadium compound) was based on renal changes resulting from doses used in preclinical safety programs. This development history highlights the significance of renal toxicity as a class effect of vanadium compounds at pharmacological doses.
7.5 Neurological and Other Systemic Effects
In vitro studies have shown that high doses of vanadium can initiate changes in hematopoiesis, and show nephrotoxic, teratogenic, and hepatotoxic activity, induce lipid peroxidation, and cause degenerative changes in the respiratory system. Studies in humans exposed to vanadium have shown the possibility of depression, tremors, neurasthenia, and other serious movement disorders including vegetative symptoms.
7.6 Carcinogenicity Classification
The International Agency for Research on Cancer (IARC) has determined that vanadium is possibly carcinogenic to humans. This classification (Group 2B) is based primarily on evidence from occupational inhalation exposure and does not specifically pertain to oral supplemental use, but should be noted in the context of long-term supplementation.
7.7 Drug Interactions and Special Populations
Vanadium might lower blood sugar. People with diabetes should check their blood sugar carefully and watch for signs of low blood sugar (hypoglycemia), particularly when vanadyl sulfate is used concurrently with insulin or other antidiabetic medications. Pregnant or breast-feeding individuals should limit intake of vanadium to the amount found in food, as not enough is known about the safety of taking larger doses. Data from animal and in vitro studies suggest that dietary antioxidants may help protect against vanadium toxicity via reduction of vanadate to vanadyl and/or formation of stable nonharmful complexes. Some dietary compounds that have shown promise include vitamins C and E, polyphenols such as those found in tea and resveratrol, phytosterols, and sulforaphane.
7.8 Bioavailability and Compound-Specific Notes
Bis-ligand oxovanadium(IV) compounds such as BMOV and BEOV have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. This means that the therapeutic doses of vanadyl sulfate required to achieve the effects observed in clinical studies are substantially higher than those of newer organic complexes, contributing to the toxicity challenge associated with the inorganic salt form.
References
- PubMed: Prolongation of insulin-induced activation of ERK 1/2 and PI 3-kinase by vanadyl sulfate (2003)
- PubMed: Inhibition of cyclic AMP dependent protein kinase by vanadyl sulfate (2006)
- PubMed: Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity (1996)
- PubMed: Multifunctional actions of vanadium compounds on insulin signaling pathways (1998)
- JCEM: Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes, Cusi et al. (2001)
- PubMed: Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus (2000)
- PubMed: A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus, Smith et al. (2008)
- PubMed: The effect of oral vanadyl sulfate on body composition and performance in weight-training athletes, Fawcett et al. (1996)
- PMC: Vanadyl Sulfate Treatment Stimulates Proliferation and Regeneration of Beta Cells in Pancreatic Islets
- PMC: Effect of aerobic exercise against vanadyl sulphate-induced nephrotoxicity and hepatotoxicity in rats
- ScienceDirect: Vanadium treatment of type 2 diabetes: a view to the future (2008)
- ScienceDirect: Vanadium in diabetes: 100 years from Phase 0 to Phase I
- PMC / NIH: Vanadium Compounds with Antidiabetic Potential (2023)
- PMC / NIH: Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications
- NIH/NCBI Bookshelf: Dietary Reference Intakes — Arsenic, Boron, Nickel, Silicon, and Vanadium (Institute of Medicine)
- ATSDR: Toxicological Profile for Vanadium — Chemical and Physical Information
- NIH/NCBI Bookshelf: Toxicological Profile for Vanadium — Health Effects
- PubMed: Effect of vanadyl sulfate on the status of lipid parameters in streptozotocin-induced diabetic rats (2006)
- PMC: New insights into mineralogenic effects of vanadate
- PubMed: A new concept — the use of vanadium complexes in the treatment of diabetes mellitus, Sakurai et al. (2002)
- Wikipedia: Vanadyl sulfate
- PubChem (NIH): Vanadyl sulfate — CID 34007
- Journal of Physiology and Pharmacology: Essentiality and toxicity of vanadium supplements in health and pathology
- Cell Biochemistry and Biophysics: Insulin signal mimicry as a mechanism for the insulin-like effects of vanadium
Go back